| $385M | ||
| $350M | ||
| $215M | ||
| $88M | ||
| $82M | ||
| $62M |
Buys | $710,500 | 1 | 100 |
Sells | $0 | 0 | 0 |
| PACE GARY W | director | 1 | $710,500 | 0 | $0 | $710,500 |
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Over the last 12 months, insiders at Cardiff Oncology, Inc. have bought $710,500 and sold $0 worth of Cardiff Oncology, Inc. stock.
On average, over the past 5 years, insiders at Cardiff Oncology, Inc. have bought $567,433 and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: PACE GARY W (director) — $710,500.
The last purchase of 290,000 shares for transaction amount of $710,500 was made by PACE GARY W (director) on 2025‑07‑30.
| 2025-07-30 | PACE GARY W | director | 290,000 0.4289% | $2.45 | $710,500 | -10.04% | ||
| 2024-12-18 | Levine James E. | Chief Financial Officer | 2,400 0.0041% | $5.00 | $12,000 | -35.97% | ||
| 2024-12-17 | Levine James E. | Chief Financial Officer | 2,752 0.0053% | $5.42 | $14,905 | -46.17% | ||
| 2024-12-16 | Levine James E. | Chief Financial Officer | 2,564 0.0048% | $3.83 | $9,820 | -28.29% | ||
| 2024-12-12 | TANNENBAUM RENEE P | director | 10,000 0.0209% | $3.42 | $34,224 | -11.16% | ||
| 2024-12-11 | PACE GARY W | director | 361,615 0.5003% | $2.60 | $940,199 | -20.95% | ||
| 2023-12-19 | PACE GARY W | director | 30,000 0.0671% | $1.37 | $41,100 | +89.71% | ||
| 2022-11-25 | Erlander Mark | Chief Executive Officer | 10,000 0.0236% | $1.43 | $14,300 | +14.03% | ||
| 2022-09-19 | White Lale | director | 15,000 0.0327% | $1.64 | $24,525 | -7.51% | ||
| 2022-09-16 | Levine James E. | Chief Financial Officer | 30,000 0.0682% | $1.56 | $46,710 | +0.95% | ||
| 2022-09-16 | Armitage James O | director | 13,000 0.0296% | $1.56 | $20,233 | +0.95% | ||
| 2022-09-15 | PACE GARY W | director | 150,000 0.3544% | $1.71 | $256,500 | -4.79% | ||
| 2022-09-15 | TANNENBAUM RENEE P | director | 10,000 0.0237% | $1.72 | $17,168 | -4.79% | ||
| 2021-09-21 | PACE GARY W | director | 30,000 0.0764% | $6.75 | $202,500 | -58.36% | ||
| 2021-09-10 | Levine James E. | Chief Financial Officer | 30,000 0.0779% | $6.47 | $194,000 | -54.92% | ||
| 2021-03-26 | Markin Rodney S | director | 2,900 0.0081% | $10.32 | $29,933 | -37.55% | ||
| 2021-03-23 | PACE GARY W | director | 10,000 0.0273% | $10.23 | $102,300 | -37.74% | ||
| 2021-03-23 | JACOB GARY S | director | 2,370 0.0066% | $10.42 | $24,689 | -37.74% | ||
| 2021-03-23 | Erlander Mark | Chief Executive Officer | 965 0.0027% | $10.34 | $9,980 | -37.74% | ||
| 2021-03-23 | Kelemen Vicki | Exec. VP and COO | 960 0.0026% | $10.31 | $9,898 | -37.74% |
| PACE GARY W | director | 1345676 1.9977% | $2.15M | 10 | 0 | +68.69% |
| Hunter Robert Merrill | 10 percent owner | 5065004 7.5192% | $8.1M | 1 | 0 | |
| BRIDGER MANAGEMENT, LLC | 2968115 4.4063% | $4.75M | 7 | 0 | <0.0001% | |
| Sheinerman Kira | director | 909090 1.3496% | $1.45M | 1 | 0 | |
| CERRONE GABRIEL | director | 719526 1.0682% | $1.15M | 5 | 0 | |
| White Lale | director | 113788 0.1689% | $182,060.80 | 2 | 0 | +295.89% |
| Levine James E. | Chief Financial Officer | 67716 0.1005% | $108,345.60 | 5 | 0 | <0.0001% |
| Tennant Stanley | director | 28839 0.0428% | $46,142.40 | 6 | 1 | <0.0001% |
| Erlander Mark | Chief Executive Officer | 24481 0.0363% | $39,169.60 | 4 | 0 | +129.42% |
| Markin Rodney S | director | 23879 0.0354% | $38,206.40 | 3 | 0 | +280.88% |
| JACOB GARY S | director | 21922 0.0325% | $35,075.20 | 2 | 0 | +280.78% |
| ZANIBONI STEVE | CFO | 21329 0.0317% | $34,126.40 | 2 | 0 | <0.0001% |
| SCHUH ANTONIUS | CEO | 20000 0.0297% | $32,000.00 | 1 | 0 | <0.0001% |
| TANNENBAUM RENEE P | director | 20000 0.0297% | $32,000.00 | 2 | 0 | <0.0001% |
| ADAMS THOMAS PHD | director | 18875 0.028% | $30,200.00 | 1 | 2 | +599.3% |
| Armitage James O | director | 13000 0.0193% | $20,800.00 | 3 | 0 | +185.01% |
| BRANCACCIO JOHN P | director | 12260 0.0182% | $19,616.00 | 3 | 0 | +279.19% |
| Kelemen Vicki | Exec. VP and COO | 6053 0.009% | $9,684.80 | 1 | 1 | <0.0001% |
| WELCH WILLIAM J | CEO | 4750 0.0071% | $7,600.00 | 1 | 0 | <0.0001% |
$5,262,089 | 154 | 5.62% | $94.13M | |
$30,470,407 | 140 | 20.39% | $100.96M | |
$9,405,928 | 107 | 12.61% | $94.77M | |
$155,630,608 | 79 | -24.53% | $90.51M | |
$17,525,882 | 60 | 5.22% | $112.05M | |
Cardiff Oncology, Inc. (CRDF) | $18,994,888 | 46 | 88.59% | $107.78M |
$6,861,925 | 44 | 8.31% | $108.39M | |
$140,595,157 | 34 | 17.93% | $99.3M | |
$36,180,184 | 32 | 41.36% | $90.05M | |
$167,701,902 | 27 | -3.07% | $123.06M | |
$38,821,584 | 20 | -2.17% | $108.17M | |
$111,692,551 | 18 | 13.51% | $109.96M | |
$156,530,514 | 13 | 45.71% | $119.82M | |
$15,799,576 | 12 | -39.52% | $121.1M | |
$9,999,920 | 10 | -40.03% | $105.19M | |
$1,073,250 | 10 | 19.46% | $98.18M | |
$2,762,881 | 8 | -10.76% | $118.57M | |
$5,524,590 | 7 | 7.40% | $101.12M | |
$68,692,148 | 6 | -39.10% | $113.63M |
| Increased Positions | 54 | +42.19% | 4M | +13.65% |
| Decreased Positions | 48 | -37.5% | 6M | -24.54% |
| New Positions | 21 | New | 702,488 | New |
| Sold Out Positions | 17 | Sold Out | 2M | Sold Out |
| Total Postitions | 134 | +4.69% | 23M | -10.89% |
| Blackrock, Inc. | $10,602.00 | 5.95% | 3.99M | +49,040 | +1.25% | 2025-09-30 |
| Vanguard Group Inc | $9,547.00 | 5.36% | 3.59M | -139,401 | -3.74% | 2025-09-30 |
| Laurion Capital Management Lp | $6,559.00 | 3.68% | 2.47M | +668,590 | +37.2% | 2025-09-30 |
| Blair William & Co/Il | $5,888.00 | 3.3% | 2.21M | -310,512 | -12.3% | 2025-09-30 |
| Acorn Capital Advisors, Llc | $5,219.00 | 2.93% | 1.96M | +553,317 | +39.28% | 2025-09-30 |
| Geode Capital Management, Llc | $4,105.00 | 2.3% | 1.54M | +44,482 | +2.97% | 2025-09-30 |
| State Street Corp | $3,049.00 | 1.71% | 1.15M | +19,833 | +1.76% | 2025-09-30 |
| Flputnam Investment Management Co | $1,589.00 | 0.89% | 597,233 | +543,370 | +1,008.8% | 2025-09-30 |
| Northern Trust Corp | $1,383.00 | 0.78% | 519,752 | -204,699 | -28.26% | 2025-09-30 |
| Goldman Sachs Group Inc | $1,210.00 | 0.68% | 454,726 | +378,392 | +495.71% | 2025-09-30 |